Paxillin
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 16: | Line 16: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | *Paxillin (residues 1-20) | + | *Paxillin LD1 (residues 1-20) |
**[[4edn]] – hPXN + beta-parvin CH2 domain - human<br /> | **[[4edn]] – hPXN + beta-parvin CH2 domain - human<br /> | ||
| Line 25: | Line 25: | ||
**[[4xgz]], [[4xh2]] – hPXN + antibody<br /> | **[[4xgz]], [[4xh2]] – hPXN + antibody<br /> | ||
**[[1ow8]], [[1ow7]] – hPXN + focal adhesion kinase focal adhesion targeting domain <br /> | **[[1ow8]], [[1ow7]] – hPXN + focal adhesion kinase focal adhesion targeting domain <br /> | ||
| + | **[[5w93]] – mPXN + P130CAS - mouse<br /> | ||
| + | |||
| + | *Paxillin LD4 (residues 20-41) | ||
| + | |||
| + | **[[6iui]] – hPXN + GIT1 PBD domain<br /> | ||
*Paxillin (residues 139-162) | *Paxillin (residues 139-162) | ||
| Line 36: | Line 41: | ||
**[[5uwh]] – hPXN + RAN + CRM1 + RANBP1<br /> | **[[5uwh]] – hPXN + RAN + CRM1 + RANBP1<br /> | ||
**[[3u3f]] – hPXN + tyrosine kinase PYK2 focal adhesion domain<br /> | **[[3u3f]] – hPXN + tyrosine kinase PYK2 focal adhesion domain<br /> | ||
| + | **[[6jmu]] – mPXN + GIT1<br /> | ||
*Paxillin proline-rich region (residues 45-54) | *Paxillin proline-rich region (residues 45-54) | ||
**[[2o9v]] – hPXN + ponsin SH3 domain<br /> | **[[2o9v]] – hPXN + ponsin SH3 domain<br /> | ||
| + | |||
| + | *Paxillin LIM4 domain (residues 527-591) | ||
| + | |||
| + | **[[6u4m]] – hPXN - NMR<br /> | ||
| + | **[[6u4n]] – hPXN + kindling-2 - NMR<br /> | ||
}} | }} | ||
Current revision
| |||||||||||
3D structures of paxillin
Updated on 17-September-2020
References
- ↑ Tumbarello DA, Brown MC, Turner CE. The paxillin LD motifs. FEBS Lett. 2002 Feb 20;513(1):114-8. PMID:11911889
- ↑ Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 1;68(1):132-42. doi: 10.1158/0008-5472.CAN-07-1998. PMID:18172305 doi:http://dx.doi.org/10.1158/0008-5472.CAN-07-1998
